TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11875330
Drug: HRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT with 2 mg estradiol valerate and 75 mug levonorgestrel (n = 15)
Study: 2125460
Drug: Betaxolol 20
Normalized name: betaxolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 20 mg daily
Study: 6775297
Drug: Lénitral 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lénitral 2.5 mg (2 capsules)
Study: 6775297
Drug: Lénitral 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lénitral 7.5 mg (1 capsule)
Study: 6775297
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin 0.6 mg
Study: 21867540
Drug: Corticosteroid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid infusion
Study: 17302019
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or conservative treatment
Study: 15197664
Drug: E-5564, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-5564, an injectable endotoxin antagonist
Study: 11325088
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (15-30 mg IV q 6 h)
Study: 9215655
Drug: Reverse transcriptase
Normalized name: Reverse transcriptase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reverse transcriptase inhibitor therapy
Study: 3322728
Drug: 50% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% reduction in intermediate‐acting insulin dose
Study: 3322728
Drug: 50% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% reduction in soluble insulin dose
Study: 18657667
Drug: Eplerenone, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone, 100 mg daily (n = 33)
Study: 18657667
Drug: Eplerenone, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone, 100 mg daily
Study: 2663800
Drug: Testolactone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testolactone (2 g/day)
Study: 28716314
Drug: Ebselen 400
Normalized name: Ebselen
DrugBank: Ebselen (DB12610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebselen 400 mg
Study: 28716314
Drug: Ebselen 200
Normalized name: Ebselen
DrugBank: Ebselen (DB12610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebselen 200 mg
Study: 28716314
Drug: Ebselen 600
Normalized name: Ebselen
DrugBank: Ebselen (DB12610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebselen 600 mg
Study: 23223314
Drug: Sirolimus (4-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (4-10 ng/mL) and prednisolone 5 mg/day
Study: 20926750
Drug: Clazosentan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (1 mg/h continuous intravenous infusion for 6 hours)
Study: 18097226
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment interruption (STI)
Study: 10423615
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg corn-oil suspension
Study: 10423615
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg corn-oil suspension
Study: 10423615
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg corn-oil suspension
Study: 10423615
Drug: Osteofix tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteofix tablet
Study: 8175218
Drug: Captopril pretreatment
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril pretreatment (6.25 mg orally about 15 min before thrombolysis) in Group A
Study: 8175218
Drug: Captopril late-treatment
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril late-treatment (administered about 3 days after thrombolysis) in Group B
Study: 8175218
Drug: Captopril late-treatment
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril late-treatment in Group B
Study: 3431098
Drug: Quik Test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quik Test Drug Screen for detection of benzoylecgonine
Study: 3431098
Drug: Quik Test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quik Test Drug Screen for benzoylecgonine
Study: 30172948
Drug: β1-preferential antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: β1-preferential antagonist (10 mg bisoprolol)
Study: 30172948
Drug: Non-preferential β1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-preferential β1 + β2-antagonist (80 mg nadolol)
Study: 23879079
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (220 mg zinc sulfate daily)
Study: 20337616
Drug: New anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New anaesthetic drug administration system
Study: 16427266
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 microg once daily via HFA-MDI without a spacer
Study: 16427266
Drug: Budesonide 320
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 320 microg once daily
Study: 10823524
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 2 microg/kg subcutaneously once a day for 5 days
Study: 1730830
Drug: Histamine diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine diphosphate (0.01 mg/ml)
Study: 1730830
Drug: Histamine diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine diphosphate (0.05 mg/ml)
Study: 1730830
Drug: Histamine diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine diphosphate (dose-response curve)
Study: 24339234
Drug: XP21279-carbidopa (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP21279-carbidopa (3 times daily)
Study: 24339234
Drug: Immediate-release carbidopa-levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carbidopa-levodopa (4 or 5 times daily)
Study: 11372005
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (0.3 mmol/kg/h)
Study: 9416716
Drug: 2 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg/kg oral clonidine
Study: 9416716
Drug: 4 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 microg/kg oral clonidine
Study: 8480273
Drug: Allopurinol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (50 mg, orally, four times a day)
Study: 8480273
Drug: DMSO (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO (500 mg, orally, four times a day)
Study: 25321394
Drug: danoprevir 100
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: danoprevir 100 mg twice daily
Study: 25321394
Drug: danoprevir 200
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: danoprevir 200 mg three times daily
Study: 25321394
Drug: danoprevir 300
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: danoprevir 300 mg twice daily
Study: 25321394
Drug: danoprevir (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: danoprevir (various doses)
Study: 19922626
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 or 40 mg once daily
Study: 15521346
Drug: 0.2% Nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Nitroglycerin ointment (0.75 mg)
Study: 15521346
Drug: 0.4% Nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% Nitroglycerin ointment (1.5 mg)
Study: 15521346
Drug: 0% Nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% Nitroglycerin ointment (placebo)
Study: 12855921
Drug: Transdermal ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal ketoprofen
Study: 11744583
Drug: Placebo tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tape treatment (control group)
Study: 9250445
Drug: Snack (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snack (240 ml of 2% milk plus one slice of toast, approximately 200 kcal)
Study: 9250445
Drug: Alanine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanine (40 g, plus 10 g of glucose, approximately 200 kcal)
Study: 3436157
Drug: Bezafibrate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (600 mg/day) with glibenclamide (5 to 15 mg/day)
Study: 3436157
Drug: Fenofibrate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (300 mg/day) with glibenclamide (5 to 15 mg/day)
Study: 3436157
Drug: Bezafibrate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (600 mg/day) with chlorpropamide (250 to 500 mg/day)
Study: 3436157
Drug: Fenofibrate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (300 mg/day) with chlorpropamide (250 to 500 mg/day)
Study: 27317442
Drug: Tedizolid 300
Normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedizolid 300 mg once daily
Study: 27317442
Drug: Tedizolid 400
Normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedizolid 400 mg once daily
Study: 27317442
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg twice daily
Study: 27317442
Drug: Tedizolid 200
Normalized name: tedizolid 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedizolid 200 mg once daily
Study: 22627991
Drug: Candesartan (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (7 days treatment)
Study: 18976976
Drug: Concurrent hysterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent hysterectomy
Study: 11521797
Drug: 5-day chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day chemotherapy regimen with Mitomycin C 12 mg/m2 day 1 and 5‐fluorouracil 500 mg/m2/24 hours for five days during weeks one and four of radiotherapy
Study: 11521797
Drug: 7-day chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day chemotherapy regimen with Mitomycin C 12 mg/m2 day 1 and 5‐fluorouracil 500 mg/m2/24 hours for seven days during weeks one and four of radiotherapy
Study: 11521797
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (chemoradiotherapy)
Study: 2662291
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide (0.1 mg/puff, 2 puffs t.d.s. for 4 weeks)
Study: 27681767
Drug: Maximum dose
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum dose of radiation therapy (RT)
Study: 24520780
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) intervention (Jianpi Shugan Recipe)
Study: 22093579
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg subcutaneously every other week for 12 weeks
Study: 11117863
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation therapy (50 Gy in 25 fractions)
Study: 11117863
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation plus brachytherapy boost (minimum peripheral tumor dose of 60 Gy)
Study: 11117863
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Conventional radiation therapy and Conventional radiation plus brachytherapy boost)
Study: 1428296
Drug: L-alpha-glycerylphosphorylcholine (alpha-GPC)
Normalized name: L-alpha-Glycerophosphorylcholine
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alpha-glycerylphosphorylcholine (alpha-GPC) 1,000 mg
Study: 1428296
Drug: Citicoline (CTC)
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (CTC) 1,000 mg
Study: 6429319
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral metoprolol (beta-blockade)
Study: 27004617
Drug: 2 portions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 portions of fruit and vegetable (FV) daily for 12 weeks
Study: 27004617
Drug: 4 portions
Normalized name: nonoxynol-9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 portions of fruit and vegetable (FV) daily for 12 weeks
Study: 27004617
Drug: 7 portions
Normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 portions of fruit and vegetable (FV) daily for 12 weeks
Study: 20445490
Drug: Gel-lubricated non-hydrophilic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-lubricated non-hydrophilic catheter
Study: 17328985
Drug: Peg-IFNalpha monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg-IFNalpha monotherapy (180 microg weekly)
Study: 17328985
Drug: Peg-IFNalpha and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg-IFNalpha and ribavirin (up to maximum tolerated dose for 48 weeks)
Study: 8381164
Drug: Early thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early thoracic irradiation (TI) - 40 Gy in 15 fractions over 3 weeks concurrent with the first cycle of etoposide and cisplatin (EP) (week 3)
Study: 8381164
Drug: Late thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late thoracic irradiation (TI) - 40 Gy in 15 fractions over 3 weeks concurrent with the last cycle of etoposide and cisplatin (EP) (week 15)
Study: 4898563
Drug: Hexoestrol, 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexoestrol, 45 mg, single injection
Study: 4898563
Drug: Stilboestrol, customary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stilboestrol, customary oral course
Study: 31141275
Drug: Body lotion
Normalized name: LOBANA BODY LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body lotion with 3HFWC
Study: 31141275
Drug: Body lotion
Normalized name: LOBANA BODY LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body lotion vehiculum (control)
Study: 31141275
Drug: Hand cream
Normalized name: TETRIX HAND CREAM,TOP
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand cream with 3HFWC
Study: 31141275
Drug: Commercial hand
Normalized name: ALCOHOL 70 mL in 100 TOPICAL CLOTH [Amazon Commercial Hand Sanitizer Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial hand cream (control)
Study: 26508709
Drug: Ivabradine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (2.5, 5, or 7.5 mg bid)
Study: 24113671
Drug: Lower-dose diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose diclofenac submicron particle capsules 35 mg TID
Study: 24113671
Drug: Lower-dose diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose diclofenac submicron particle capsules 18 mg TID
Study: 15304586
Drug: Acetaminophen 500
Normalized name: acetaminophen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg before and 6 and 12 hours after each injection
Study: 15304586
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg before and 6 and 12 hours after each injection
Study: 15304586
Drug: Prednisone 60
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 60 mg daily for 1 week, plus tapering
Study: 11182530
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine patches (N = 18)
Study: 11182530
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches (N = 20)
Study: 9217952
Drug: Successful amnioinfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful amnioinfusion (infused solution alleviated oligohydramnios for > 48 hours)
Study: 9217952
Drug: Unsuccessful amnioinfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsuccessful amnioinfusion (infused solution rapidly lost)
Study: 3110524
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg RO 15-1788
Study: 3110524
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg RO 15-1788
Study: 3110524
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg RO 15-1788
Study: 28782145
Drug: Camicinal 150
Normalized name: Camicinal
DrugBank: Camicinal (DB12567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camicinal 150 mg
Study: 27439601
Drug: Intracoronary autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary autologous bone marrow cell (BMC) infusion
Study: 27439601
Drug: State-of-the-art therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: State-of-the-art therapy (control group)
Study: 22082672
Drug: Celivarone 50
Normalized name: Celivarone
DrugBank: Celivarone (DB16012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celivarone 50 mg/d
Study: 22082672
Drug: Celivarone 100
Normalized name: Celivarone
DrugBank: Celivarone (DB16012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celivarone 100 mg/d
Study: 22082672
Drug: Celivarone 300
Normalized name: Celivarone
DrugBank: Celivarone (DB16012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celivarone 300 mg/d
Study: 22082672
Drug: Amiodarone 200
Normalized name: amiodarone 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 200 mg/d (after loading dose of 600 mg/d for 10 days)
Study: 19408831
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg body weight s.c. twice daily
Study: 19408831
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (Heparin - 'Biochemie' 25.000 IU/5 ml)
Study: 11318080
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg once daily, titrated to 20 mg once daily and then 40 mg once daily as needed.
Study: 11318080
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg once daily, titrated to 40 mg once daily and then 40 mg twice daily as needed.
Study: 3311275
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg twice daily for 3 days as prophylaxis
Study: 27943311
Drug: FV-100 200
Normalized name: HORSERADISH 10 g in 100 mL TOPICAL LIQUID [NWK A-FV]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FV-100 200 mg QD
Study: 27943311
Drug: FV-100 400
Normalized name: HORSERADISH 10 g in 100 mL TOPICAL LIQUID [NWK A-FV]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FV-100 400 mg QD
Study: 27943311
Drug: Valacyclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1000 mg TID
Study: 22554294
Drug: MHA (microparticle
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHA (microparticle size) coated non-etched implants (G1)
Study: 22554294
Drug: NHA (nanoparticle
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHA (nanoparticle size) coated non-etched implants (G2)
Study: 22554294
Drug: MHA mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHA mixed with whole human blood without surface treatment (G5)
Study: 22554294
Drug: NHA mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHA mixed with whole human blood without surface treatment (G6)
Study: 21216835
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and mycophenolate mofetil therapy (COMBO)
Study: 18053320
Drug: Exenatide 5
Normalized name: EXENATIDE 5MCG/DOSE 1.2ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 5 µg BID for 30 weeks, then 5 µg BID for 4 weeks, then 10 µg BID for ≥ 3 years
Study: 12571543
Drug: Nurse-monitored structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-monitored structured care program with uptitration of enalapril to a target dose of 10 mg twice a day
Study: 1458072
Drug: Amphotericin in
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin in fat emulsion (2 g/l fat emulsion)
Study: 15123861
Drug: Phenobarbitone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (5 mg/kg/day for 3 days)
Study: 9566630
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) based on propofol and alfentanil
Study: 9471197
Drug: Thymostimulin +
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin + concurrent hyperfractionated carboplatin and irradiation
Study: 9471197
Drug: Concurrent hyperfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent hyperfractionated carboplatin and irradiation
Study: 1826920
Drug: Back school
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back school therapy
Study: 7074980
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg naloxone administered to women on days 2‐4 of the puerperium
Study: 29895376
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of elemental calcium as calcium citrate
Study: 24793078
Drug: ABH Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABH Gel (lorazepam, diphenhydramine, haloperidol)
Study: 24793078
Drug: ABH Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABH Gel
Study: 24793078
Drug: ABH Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABH Gel and Placebo
Study: 20881623
Drug: Physical examinations
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical examinations by an occupational medicine physician